TY - JOUR
T1 - Obesity in Cystic fibrosis
T2 - prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry
AU - Szentpetery, Sylvia
AU - Fernandez, Gabriela S.
AU - Schechter, Michael S.
AU - Jain, Raksha
AU - Flume, Patrick A.
AU - Fink, Aliza K.
N1 - Publisher Copyright:
© 2022
PY - 2022/9
Y1 - 2022/9
N2 - Strong emphasis has been placed historically on increasing weight and improving nutritional status in cystic fibrosis patients. Due to correlation between nutritional indices (e.g. BMI) and lung function, CF Nutrition Guidelines have recommended BMI percentile goals at the 50th percentile or higher. Trends in increasing BMI across CF programs suggest significantly increasing proportions of overweight and obese status in recent years. We identify that between 2000 and 2019 there has been a relative decrease in underweight status by ∼40%, simultaneously with a > 300% increase in overweight status, and >400% increase in obesity. Patient specific factors associated with higher prevalence of obesity included age ≥46, living in a zip code where the median income was < $20,000, having at least one allele with a class IV or V mutation, a ppFEV1 >90 prescribed ivacaftor, and not prescribed pancreatic enzymes. Program specific factors were not identified.
AB - Strong emphasis has been placed historically on increasing weight and improving nutritional status in cystic fibrosis patients. Due to correlation between nutritional indices (e.g. BMI) and lung function, CF Nutrition Guidelines have recommended BMI percentile goals at the 50th percentile or higher. Trends in increasing BMI across CF programs suggest significantly increasing proportions of overweight and obese status in recent years. We identify that between 2000 and 2019 there has been a relative decrease in underweight status by ∼40%, simultaneously with a > 300% increase in overweight status, and >400% increase in obesity. Patient specific factors associated with higher prevalence of obesity included age ≥46, living in a zip code where the median income was < $20,000, having at least one allele with a class IV or V mutation, a ppFEV1 >90 prescribed ivacaftor, and not prescribed pancreatic enzymes. Program specific factors were not identified.
KW - Cystic fibrosis
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=85127647180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127647180&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2022.03.010
DO - 10.1016/j.jcf.2022.03.010
M3 - Article
C2 - 35396178
AN - SCOPUS:85127647180
SN - 1569-1993
VL - 21
SP - 777
EP - 783
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 5
ER -